Modulation of Beta-amyloid Levels in CSF and Plasma by GSK933776 in Patients With Mild Alzheimer's Disease or Mild Cognitive Impairment
GSK933776, developed by GlaxoSmithKline, targets beta-amyloid modulation in patients with mild Alzheimer's disease and mild cognitive impairment. Given the increasing prevalence of Alzheimer's disease and the significant unmet medical need, this asset holds potential commercial value in a market projected to grow substantially. The competitive landscape includes other amyloid-targeting therapies, necessitating a thorough evaluation of GSK933776's efficacy and safety profile to establish a differentiated market position. The completion of this Phase 1 trial suggests a commitment to advancing the drug through clinical development, which may attract partnerships or investment opportunities.
Indication: Alzheimer's Disease
Modality: protein therapy
Target: Beta-amyloid levels modulation in cerebrospinal fluid (CSF) and plasma.
Sponsor: GlaxoSmithKline
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 24, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Beta-amyloid levels modulation in cerebrospinal fluid (CSF) and plasma.
View original source fields
Condition raw: Alzheimer's Disease
Condition normalized: Alzheimer's Disease
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Beta-amyloid levels modulation in cerebrospinal fluid (CSF) and plasma.
Target normalized: Beta-amyloid levels modulation in cerebrospinal fluid (CSF) and plasma.